<DOC>
	<DOCNO>NCT00270699</DOCNO>
	<brief_summary>Dengue fever , cause dengue virus , major health problem tropical subtropical region world . The purpose study test safety immune response new dengue virus vaccine healthy adult .</brief_summary>
	<brief_title>Safety Immune Response Dengue Virus Vaccine ( rDEN4delta30-200,201 ) Healthy Adults</brief_title>
	<detailed_description>Dengue virus cause dengue fever severe dengue hemorrhagic fever/shock syndrome . More 2 billion people live tropical subtropical region world risk dengue virus infection , lead cause hospitalization death child several tropical Asian country . This study evaluate safety immunogenicity live attenuate dengue virus vaccine call rDEN4delta30-200,201 . This vaccine derive rDEN4delta30 , another dengue virus vaccine candidate show safe immunogenic Phase I II trial healthy adult . This study last 180 day . There three cohort dose de-escalation study . Participants Cohort 1 randomly assign receive high dose rDEN4delta30-200,201 placebo study entry . Cohort 2 begin safety review participant Cohort 1 . Participants Cohort 2 receive low dose rDEN4delta30-200,201 placebo . Cohort 3 begin safety review participant Cohort 2 . Participants Cohort 3 receive lowest dose rDEN4delta30-200,201 placebo . After vaccination , participant ask monitor temperature every day 16 day . Study visit occur every day vaccination Day 16 , follow four additional visit select day Day 180 . Blood collection , vital sign measurement , target physical exam occur study visit . Some participant ask undergo skin biopsy additional blood collection select visit .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Willing follow duration study Willing use acceptable method contraception Good general health Clinically significant neurologic , heart , lung , liver , rheumatologic , autoimmune , kidney disease Behavioral , cognitive , psychiatric disease , opinion investigator , may affect ability volunteer understand cooperate study Laboratory abnormality study screen Alcohol drug abuse within 12 month prior study entry History severe allergic reaction anaphylaxis Emergency room visit hospitalization severe asthma within 6 month prior study entry HIV1 infect Hepatitis C virus infect Hepatitis B surface antigen positive Known immunodeficiency syndrome Use corticosteroid immunosuppressive drug within 30 day prior study entry . Participants use topical nasal corticosteroid exclude . Live vaccine within 4 week prior study entry Killed vaccine within 2 week prior study entry Blood product within 6 month prior study entry Previously receive licensed experimental yellow fever dengue vaccine Surgical removal spleen History dengue virus infection flavivirus infection ( e.g. , yellow fever virus , St. Louis encephalitis virus , West Nile virus , Japanese encephalitis virus ) Other condition , opinion investigator , would affect participant 's participation study Plan travel area dengue infection common Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Dengue Vaccine</keyword>
	<keyword>Dengue Virus</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>Dengue Shock Syndrome</keyword>
</DOC>